Vaccine Stocks Dip Amid Reports of Potential Booster Shot Authorization

Strategic Insights -

As the Centers for Disease Control and Prevention (CDC) waits for the Food and Drug Administration (FDA) to decide on authorizing Pfizer and BioNTech's COVID-19 booster shot for younger teens, vaccine stocks experienced a downturn, with BioNTech stock falling 0.3% and Pfizer stock slipping 0.7%. The potential decision, which could see children as young as 12 receive booster shots, is likely to be a game-changer for vaccine stocks, considering the Pfizer-BioNTech vaccine has shown 100% protection against COVID-19 for four months in testing.

Key Takeaways:

  • The FDA is considering authorizing Pfizer and BioNTech's COVID-19 booster shot for children aged 12-15, which could lead to a significant increase in vaccine demand and bolster vaccine stocks.
  • So far, children as young as 5 can receive two primary shots from Pfizer and BioNTech, but booster shots are only available to people aged 16 and older.
  • The CDC will swiftly follow the FDA's decision and is hoping to have an update within days to weeks.
  • The Pfizer-BioNTech vaccine has shown 100% protection against COVID-19 for four months in testing.
  • Pfizer has not officially asked the FDA to authorize boosters for the 12-15 age group, but the company is now requesting official approval of the two-dose vaccine for this age group.

Statistics:

  • BioNTech stock fell 0.3% to 240.61, while Pfizer stock slipped 0.7% to 57.58.
  • The Pfizer-BioNTech vaccine has shown 100% protection against COVID-19 for four months in testing.
  • There were 30 cases of symptomatic COVID-19 in the placebo group, and none among those who received the vaccine.
  • BioNTech stock lost more than 5% on Tuesday, while Pfizer stock fell 2% over the same period.

Sources:

  • "U.S. officials may soon authorize Pfizer and BioNTech's COVID-19 booster shot for younger teens." CNN
  • Rochelle Walensky, Director of the Centers for Disease Control and Prevention, quoted in CNN
  • "BioNTech and Pfizer stock declined amid reports of potential booster shot authorization." CNBC